Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors. 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 84-page Updated Executive Informational Overview (EIO) on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: geovax

Crystal Research Associates has issued an 11-page Quarterly Update on specialty biotech pharmaceutical research and development (R&D) company, FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), detailing the Company's recent news and developments—including its recent permission from the U.S. FDA on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19 (the disease caused by the SARS-CoV-2 virus)—as well as its recent financial position. The report is available for download below.

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), ultramicronized-PEA, fsd, FSD201, medical cannabis, covid19, coronovirus

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

An Executive Informational Overview (EIO) is now available on StageZero Life Sciences, Ltd (SZLS-TSX), a revenue-generating innovator in the liquid biopsy space, dedicated to the early detection of cancer and multiple disease states. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: liquid biopsy, blood-based diagnostics, ColonSentry, Sentinel Principle, EarlyCDT®-Lung, BreastSentry, StageZero Life Sciences

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), Prismic Pharmaceuticals, ultramicronized-PEA, fsd, SciCann Therapeutics, Solarvest BioEnergy Inc., FSD201, medical cannabis, Canntab Therapeutics Ltd, Huge Shops, Aura Health Inc.

An Executive Informational Overview (EIO) is now available on Reliance Global Group, Inc. (RELI-OTC), a diversified holding company investing in real estate and insurance markets. The 48-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: reliance global group, multi-family properties, insurance, insurance carriers, Employee Benefit Solutions, The Referral Depot, reliance global holdings, RELI, insurance agencies, REIT, real estate, U.S. Benefits Alliance, Commercial Solutions of Insurance Agency, Southwestern Montana Insurance Center, Fortman Insurance Agency

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv